Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Am J Med. 2020 Jul 3;134(1):122–128.e3. doi: 10.1016/j.amjmed.2020.05.038

Figure 2.

Figure 2

Spectral domain-optical coherence tomography images of the same macular segmentation line at baseline and monthly follow-up visits in a patient naı¨ve to intravitreal anti-vascular endothelial growth factor (VEGF) therapy. There was a 59% reduction in retinal fluid at 1 month; retinal fluid completely resolved at the same macular segmentation line at month 2, and fluid remained stable up to month 3 without anti-VEGF injections. Collectively, all macular segmentation lines revealed a 92% total retinal fluid decrease at 3 months.